The association between albumin-corrected calcium and prognosis in patients with cardiac arrest: a retrospective study based on the MIMIC-IV database

Table 3 Cox proportional hazard analysis of all-cause mortality in patients with CA between the three groups

	Variable	Model I			Model II			Model III
	Variable	HR	95% CI	P-value	HR	95% CI	P-value	HR	95% CI	P-value
Original cohort	90-day mortality
	8.86–10.32	1			1			1
	< 8.86	1.188	0.972–1.453	0.092	1.279	1.040–1.573	0.020	1.317	1.069–1.621	0.010
	> 10.32	1.673	1.219–2.296	0.001	1.411	1.021–1.949	0.037	1.391	1.005–1.926	0.047
	360-day mortality
	8.86–10.32	1			1			1
	< 8.86	1.132	0.935–1.371	0.205	1.248	1.024–1.520	0.028	1.285	1.054–1.567	0.013
	> 10.32	1.733	1.285–2.337	< 0.001	1.488	1.096–2.020	0.011	1.477	1.086–2.009	0.013
Weighted cohort	90-day mortality
	8.86–10.32	1			1			1
	< 8.86	1.279	1.025–1.596	0.029	1.249	0.992–1.573	0.059	1.301	1.029–1.645	0.028
	> 10.32	1.589	1.178–2.143	0.002	1.458	1.074–1.979	0.016	1.426	1.025–1.984	0.035
	360-day mortality
	8.86–10.32	1			1			1
	< 8.86	1.255	1.015–1.552	0.036	1.226	0.982–1.532	0.073	1.281	1.022–1.604	0.031
	> 10.32	1.595	1.192–2.134	0.002	1.475	1.098–1.982	0.010	1.457	1.054–2.014	0.023

Original cohort:
Model I: No covariate adjustments were made. Model II: Adjusted for age, SOFA score, anion gap, phosphate, and RDW
Model III: Built upon model II, further adjusted for the comorbidities including congestive heart failure, VF, cerebrovascular disease, and the proportion of receiving transthoracic echocardiography and norepinephrine
Matched cohort:
Model I: No covariate adjustments were made
Model II: Adjusted for age, SOFA score, WBC count, hemoglobin, RDW, MCV, AST, BUN, creatinine, anion gap, and phosphate
Model III: Built upon model II, further adjusted for the comorbidities including congestive heart failure, VF, cerebrovascular disease, malignant tumor, and the usage of norepinephrine

ISSN: 2047-783X